Video

Dr. Carey on Treating Triple-Negative Breast Cancer

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Carey says the main challenge in treating triple-negative breast cancer is that physicians are limited to chemotherapy outside of clinical trials. However, there are relatively low-toxicity chemotherapy regimens that are used in the treatment of these patients.

Triple-negative breast cancer tends to behave like other subsets where taxanes are effective, and it has been shown that platinum drugs are as effective as taxanes in the first-line setting, Carey says.

Even though treatment in the space is limited to chemotherapy, Carey says there are 4-5 agents that can be used for the treatment of triple-negative breast cancer.

<<<

View more from the 32nd Annual Miami Breast Cancer Conference

Related Videos
Sagar D. Sardesai, MBBS
DB-12
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP